BACKGROUND: Patients with advanced hepatobiliary cancer (HBC) have a dismal prognosis and limited treatment options. Immunotherapy has been considered as a promising treatment, especially for cancers not amenable to surgery. METHODS: Between 2004, and 2015, patients diagnosed with hepatocellular carcinoma (HCC), intra- and extrahepatic cholangiocarcinoma and gallbladder cancer (GBC) were identified in the National Cancer Database. RESULTS: Among 249,913 patients with HBC, only 585 (0.2%) patients received immunotherapy. Among patients who received immunotherapy, most patients were diagnosed between 2012 and 2015, had private insurance, as well as an income ≥$46,000 and were treated at an academic facility. The use of immunotherapy among HBC patients varied by diagnosis (HCC, 67.7%; bile duct cancer, 14%). On multivariable analysis, a more recent period of diagnosis (OR 1.80, 95% CI: 1.44-2.25), median income >$46,000 (OR 1.43, 95% CI: 1.11-1.87), and higher tumor stage (stage III, OR 2.22, 95% CI: 1.65-3.01; stage IV, OR 3.24, 95% CI: 2.41-4.34) were associated with greater odds of receiving immunotherapy. CONCLUSIONS: Overall utilization of immunotherapy in the US among patients with HBC was very low, yet has increased over time. Certain socioeconomic factors were associated with an increased likely of receiving immunotherapy, suggesting disparities in access of patients with lower socioeconomic status. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.
BACKGROUND: Patients with advanced hepatobiliary cancer (HBC) have a dismal prognosis and limited treatment options. Immunotherapy has been considered as a promising treatment, especially for cancers not amenable to surgery. METHODS: Between 2004, and 2015, patients diagnosed with hepatocellular carcinoma (HCC), intra- and extrahepatic cholangiocarcinoma and gallbladder cancer (GBC) were identified in the National Cancer Database. RESULTS: Among 249,913 patients with HBC, only 585 (0.2%) patients received immunotherapy. Among patients who received immunotherapy, most patients were diagnosed between 2012 and 2015, had private insurance, as well as an income ≥$46,000 and were treated at an academic facility. The use of immunotherapy among HBC patients varied by diagnosis (HCC, 67.7%; bile duct cancer, 14%). On multivariable analysis, a more recent period of diagnosis (OR 1.80, 95% CI: 1.44-2.25), median income >$46,000 (OR 1.43, 95% CI: 1.11-1.87), and higher tumor stage (stage III, OR 2.22, 95% CI: 1.65-3.01; stage IV, OR 3.24, 95% CI: 2.41-4.34) were associated with greater odds of receiving immunotherapy. CONCLUSIONS: Overall utilization of immunotherapy in the US among patients with HBC was very low, yet has increased over time. Certain socioeconomic factors were associated with an increased likely of receiving immunotherapy, suggesting disparities in access of patients with lower socioeconomic status. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.
Entities:
Keywords:
Immunotherapy; hepatobiliary cancer (HBC); socioeconomic status; trends
Authors: Thomas T DeLeon; Yumei Zhou; Bolni M Nagalo; Raquel T Yokoda; Daniel H Ahn; Ramesh K Ramanathan; Marcela A Salomao; Bashar A Aqel; Amit Mahipal; Tanios S Bekaii-Saab; Mitesh J Borad Journal: Immunotherapy Date: 2018-09 Impact factor: 4.196
Authors: Andrew J Lepisto; Arthur J Moser; Herbert Zeh; Kenneth Lee; David Bartlett; John R McKolanis; Brian A Geller; Amy Schmotzer; Douglas P Potter; Theresa Whiteside; Olivera J Finn; Ramesh K Ramanathan Journal: Cancer Ther Date: 2008
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Zaid Al-Qurayshi; Jason E Crowther; John B Hamner; Christopher Ducoin; Mary T Killackey; Emad Kandil Journal: Anticancer Res Date: 2018-05 Impact factor: 2.480
Authors: Omid Salehi; Eduardo A Vega; Sebastian Mellado; Michael J Core; Mu Li; Olga Kozyreva; Onur C Kutlu; Richard Freeman; Claudius Conrad Journal: J Gastrointest Surg Date: 2022-04-08 Impact factor: 3.267
Authors: Ruth P Norris; Rosie Dew; Linda Sharp; Alastair Greystoke; Stephen Rice; Kristina Johnell; Adam Todd Journal: BMC Med Date: 2020-10-23 Impact factor: 8.775